MediciNova (MNOV) Competitors $1.66 -0.02 (-1.19%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MNOV vs. VRCA, KZR, HOOK, NXTC, VYNE, ZVRA, ACB, ZURA, ITOS, and QUREShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Verrica Pharmaceuticals (VRCA), Kezar Life Sciences (KZR), Hookipa Pharma (HOOK), NextCure (NXTC), VYNE Therapeutics (VYNE), Zevra Therapeutics (ZVRA), Aurora Cannabis (ACB), Zura Bio (ZURA), iTeos Therapeutics (ITOS), and uniQure (QURE). These companies are all part of the "medical" sector. MediciNova vs. Verrica Pharmaceuticals Kezar Life Sciences Hookipa Pharma NextCure VYNE Therapeutics Zevra Therapeutics Aurora Cannabis Zura Bio iTeos Therapeutics uniQure MediciNova (NASDAQ:MNOV) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership. Do analysts prefer MNOV or VRCA? Verrica Pharmaceuticals has a consensus target price of $11.40, indicating a potential upside of 645.10%. Given Verrica Pharmaceuticals' higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than MediciNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AVerrica Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger earnings and valuation, MNOV or VRCA? MediciNova has higher earnings, but lower revenue than Verrica Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1M81.42-$8.56M-$0.16-10.37Verrica Pharmaceuticals$5.12M12.75-$67M-$1.88-0.81 Which has more risk and volatility, MNOV or VRCA? MediciNova has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Does the media refer more to MNOV or VRCA? In the previous week, MediciNova and MediciNova both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.65 beat MediciNova's score of 0.37 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in MNOV or VRCA? 9.9% of MediciNova shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 14.9% of MediciNova shares are owned by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor MNOV or VRCA? MediciNova received 42 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. However, 64.98% of users gave Verrica Pharmaceuticals an outperform vote while only 49.41% of users gave MediciNova an outperform vote. CompanyUnderperformOutperformMediciNovaOutperform Votes20949.41% Underperform Votes21450.59% Verrica PharmaceuticalsOutperform Votes16764.98% Underperform Votes9035.02% Is MNOV or VRCA more profitable? MediciNova has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. MediciNova's return on equity of -13.37% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -13.37% -12.67% Verrica Pharmaceuticals -625.06%-591.84%-100.16% SummaryVerrica Pharmaceuticals beats MediciNova on 9 of the 16 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.42M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-10.379.74115.4815.20Price / Sales81.42381.431,483.2092.69Price / CashN/A47.3339.6534.06Price / Book1.315.324.665.02Net Income-$8.56M$153.56M$119.06M$225.46M7 Day PerformanceN/A0.12%0.80%0.37%1 Month Performance-17.00%15.23%5.66%3.57%1 Year Performance-12.17%41.16%36.76%29.43% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova0.1705 of 5 stars$1.66-1.2%N/A-11.7%$81.42M$1M-10.3710Analyst ForecastVRCAVerrica Pharmaceuticals4.1939 of 5 stars$1.51+0.7%$11.40+655.0%-58.1%$64.05M$13.91M-0.8040Gap UpKZRKezar Life Sciences4.0456 of 5 stars$0.79-2.5%$4.50+472.7%-5.2%$57.33M$7M-0.5860Stock SplitHOOKHookipa Pharma3.3497 of 5 stars$3.78-3.3%$44.67+1,081.7%-8.8%$45.59M$20.13M-0.8856News CoveragePositive NewsNXTCNextCure3.888 of 5 stars$1.39+3.0%$6.00+331.7%+24.3%$38.88MN/A-0.6390Upcoming EarningsPositive NewsGap UpVYNEVYNE Therapeutics2.8869 of 5 stars$2.67-0.7%$5.75+115.4%-11.4%$38.79M$486,000.00-1.0330Gap UpZVRAZevra Therapeutics2.8918 of 5 stars$7.75-1.9%$20.83+168.8%+88.8%$324.36M$23.69M-4.6165Upcoming EarningsPositive NewsACBAurora Cannabis0.7124 of 5 stars$5.93+4.6%N/A+22.3%$323.46M$278.98M-8.471,073Upcoming EarningsZURAZura Bio2.5793 of 5 stars$4.74+3.0%$17.33+265.7%-6.8%$318.58MN/A0.003ITOSiTeos Therapeutics2.3392 of 5 stars$8.72+1.4%$30.50+249.8%-11.1%$318.45M$12.60M-2.9190Upcoming EarningsQUREuniQure2.086 of 5 stars$6.54+0.8%$19.50+198.4%+1.7%$318.25M$15.84M-1.10500Upcoming Earnings Related Companies and Tools Related Companies VRCA Competitors KZR Competitors HOOK Competitors NXTC Competitors VYNE Competitors ZVRA Competitors ACB Competitors ZURA Competitors ITOS Competitors QURE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNOV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
